Advance the Development of NK, Gamma-Delta T, Macrophage & NKT Cell Therapies to Develop Cost-Effective Treatments for Liquid and Solid Tumors

The Innate Killer Summit returns for its 7th year as the industry-defining forum advancing the field to achieve clinical success. Spanning the current drug development landscape, from improving gene editing transduction in discovery to cryopreservation and CMC in scaled manufacturing, this is the definitive meeting to focus on the clinical and scaled phase development of innate cell therapies.

Get your copy of the 2022 agenda here.

Join over 200 experts to characterize and contrast cell sources, supercharge combinations, optimize CMC workflows, examine expansion protocols for high-quality products at scale, and move the field towards persistent, scalable, and cost-effective innate immune cell therapies.

Promising unpublished data, interactive discussion, and engaging networking opportunities join the 7th Innate Killer Summit to forge new collaborations and capitalize on the clinical potential of innate immune cell therapies.

Expert Speakers for 2022 Included:

Mark Lowdell

Chief Scientific Officer

INmune Bio

Anahid Jewett

Professor & Director Tumor Immunology Laboratory


Michael DeRidder

SVP Corporate Strategy and New Product Planning

Catamaran Bio

Todd Fehniger

Professor of Medicine

Washington University School of Medicine, St. Louis

2022 Partners:


Program Partners

Industry Partners

Innovation Partners

Exhibition Partners

Event Partners